Literature DB >> 7633941

Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism.

I C Klausen1, L Hegedüs, P S Hansen, F E Nielsen, L U Gerdes, O Faergeman.   

Abstract

Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL) particle in which apolipoprotein B-100 (apoB) is attached to a glycoprotein called apolipoprotein(a) [apo(a)]. Apo(a) has several genetically determined phenotypes differing in molecular weight, to which Lp(a) concentrations in plasma are inversely correlated. High plasma levels of Lp(a) are associated with atherosclerotic diseases. It is therefore of interest to study whether factors other than the apo(a) gene locus are involved in the regulation of Lp(a) concentrations. We measured plasma concentrations of Lp(a) and other lipoproteins and determined apo(a) phenotypes in 31 patients with hyperthyroidism, before and after the patients had become euthyroid by treatment. The mean concentration of LDL cholesterol rose from 2.67 to 3.88 mmol/l (P < 0.01), apoB rose from 0.79 to 1.03 g/l (P < 0.01), and the median Lp(a) concentration increased from 9.74 to 18.97 mg/dl (P < 0.01) on treatment. Lp(a) concentrations were inversely associated to the size of the apo(a) molecule both before (P < 0.01) and after treatment (P < 0.01). The increase in Lp(a) was significant in patients with high molecular weight apo(a) phenotypes (n = 9; P < 0.01) and in patients with low molecular weight apo(a) phenotypes (n = 16; P < 0.01), but not in those with apo(a) "null types" (n = 6; P = 0.5). The low levels LDL cholesterol and apoB in untreated hyperthyroidism may result from increased LDL receptor activity. The increase in Lp(a) levels were not correlated with the increase in LDL cholesterol or apoB.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7633941     DOI: 10.1007/bf00203618

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  41 in total

1.  Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis.

Authors:  C Lackner; E Boerwinkle; C C Leffert; T Rahmig; H H Hobbs
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  The determination of thyroid volume by ultrasound and its relationship to body weight, age, and sex in normal subjects.

Authors:  L Hegedüs; H Perrild; L R Poulsen; J R Andersen; B Holm; P Schnohr; G Jensen; J M Hansen
Journal:  J Clin Endocrinol Metab       Date:  1983-02       Impact factor: 5.958

3.  Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.

Authors:  L A Carlson; A Hamsten; A Asplund
Journal:  J Intern Med       Date:  1989-10       Impact factor: 8.989

4.  Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers.

Authors:  E Marth; G Cazzolato; G Bittolo Bon; P Avogaro; G M Kostner
Journal:  Ann Nutr Metab       Date:  1982       Impact factor: 3.374

5.  Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a).

Authors:  I C Klausen; F E Nielsen; L Hegedüs; L U Gerdes; P Charles; O Faergeman
Journal:  Metabolism       Date:  1992-08       Impact factor: 8.694

6.  Effect of thyroid function on concentrations of lipoprotein(a)

Authors:  H Engler; W F Riesen
Journal:  Clin Chem       Date:  1993-12       Impact factor: 8.327

7.  Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans.

Authors:  R P Mensink; P L Zock; M B Katan; G Hornstra
Journal:  J Lipid Res       Date:  1992-10       Impact factor: 5.922

8.  Serum lipids and apolipoproteins A-I, A-II, and B in hyperthyroidism before and after treatment.

Authors:  E Muls; V Blaton; M Rosseneu; E Lesaffre; G Lamberigts; P De Moor
Journal:  J Clin Endocrinol Metab       Date:  1982-09       Impact factor: 5.958

9.  Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.

Authors:  I C Klausen; L U Gerdes; H Meinertz; F A Hansen; O Faergeman
Journal:  Eur J Clin Invest       Date:  1993-04       Impact factor: 4.686

10.  Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects.

Authors:  B L Knight; Y F Perombelon; A K Soutar; D P Wade; M Seed
Journal:  Atherosclerosis       Date:  1991-04       Impact factor: 5.162

View more
  1 in total

1.  Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease.

Authors:  Melpomeni Peppa; Grigoria Betsi; George Dimitriadis
Journal:  J Lipids       Date:  2011-07-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.